After UBS initiates at Buy, cites “best-in-group” growth in specialty pharma, Amneal shares rise
Corroborated by 2 sources from 2 publishers
ushealth4h ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, uBS said the stock’s roughly 14% decline over the past two months presents an opportunity in the specialty pharmaceuticals group, where it views Amneal as having a stronger growth profile relative to peers.